Production of antiviral “OP7 chimera” defective interfering particles free of infectious virus

• Published in: Applied microbiology and biotechnology 2024-12, Vol.108 (1), p.97-97, Article 97
• Main Authors: Pelz, Lars, Dogra, Tanya, Marichal-Gallardo, Pavel, Hein, Marc Dominique, Hemissi, Ghada, Kupke, Sascha Young, Genzel, Yvonne, Reichl, Udo
• Format: Article
• Language: English
• Subjects: Antiviral agents; Antiviral drugs; Biomedical and Life Sciences; Bioreactors; Biotechnological Products and Process Engineering; Biotechnology; Cell culture; Chimeras; Flasks; Gene deletion; Genetic engineering; Genomes; Inactivation; Influenza A; Life Sciences; Microbial Genetics and Genomics; Microbiology; Mutation; Perfusion; Virions; Viruses
• ISSN: 0175-7598; 1432-0614
• DOI: 10.1007/s00253-023-12959-6

Defective interfering particles (DIPs) of influenza A virus (IAV) are suggested for use as broad-spectrum antivirals. We discovered a new type of IAV DIP named “OP7” that carries point mutations in its genome segment (Seg) 7 instead of a deletion as in conventional DIPs (cDIPs). Recently, using genetic engineering tools, we generated “OP7 chimera DIPs” that carry point mutations in Seg 7 plus a deletion in Seg 1. Together with cDIPs, OP7 chimera DIPs were produced in shake flasks in the absence of infectious standard virus (STV), rendering UV inactivation unnecessary. However, only part of the virions harvested were OP7 chimera DIPs (78.7%) and total virus titers were relatively low. Here, we describe the establishment of an OP7 chimera DIP production process applicable for large-scale production. To increase total virus titers, we reduced temperature from 37 to 32 °C during virus replication. Production of almost pure OP7 chimera DIP preparations (99.7%) was achieved with a high titer of 3.24 log 10 (HAU/100 µL). This corresponded to an 11-fold increase relative to the initial process. Next, this process was transferred to a stirred tank bioreactor resulting in comparable yields. Moreover, DIP harvests purified and concentrated by steric exclusion chromatography displayed an increased interfering efficacy in vitro. Finally, a perfusion process with perfusion rate control was established, resulting in a 79-fold increase in total virus yields compared to the original batch process in shake flasks. Again, a very high purity of OP7 chimera DIPs was obtained. This process could thus be an excellent starting point for good manufacturing practice production of DIPs for use as antivirals. Key points • Scalable cell culture-based process for highly effective antiviral OP7 chimera DIPs • Production of almost pure OP7 chimera DIPs in the absence of infectious virus • Perfusion mode production and purification train results in very high titers